Clinical Trial Update: Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating camrelizumab (SHR-1210) with apatinib-based therapies for AFP-producing gastric cancer or gastroesophageal junction adeno…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• apatinib-based therapies (apatinib)

Snippet

Sponsor: Peking University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN